XOMA (NASDAQ:XOMA) Rating Reiterated by HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $74.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 191.22% from the stock’s previous close.

XOMA Stock Performance

Shares of XOMA stock opened at $25.41 on Thursday. The company has a market capitalization of $295.77 million, a PE ratio of -6.29 and a beta of 0.58. The company has a debt-to-equity ratio of 1.34, a quick ratio of 8.68 and a current ratio of 8.68. The company has a 50-day simple moving average of $24.86 and a two-hundred day simple moving average of $20.38. XOMA has a one year low of $13.48 and a one year high of $27.00.

XOMA (NASDAQ:XOMA) last announced its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The firm had revenue of $1.83 million during the quarter, compared to the consensus estimate of $1.01 million. XOMA had a negative return on equity of 25.17% and a negative net margin of 886.91%. Research analysts expect that XOMA will post -1.73 EPS for the current fiscal year.

Institutional Investors Weigh In On XOMA

A hedge fund recently bought a new stake in XOMA stock. Barclays PLC purchased a new position in shares of XOMA Co. (NASDAQ:XOMA) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,468 shares of the biotechnology company’s stock, valued at approximately $28,000. 95.92% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.